20[™] INTERNATIONAL EXPERTS SYMPOSIUM

CRITICAL ISSUES

in aortic endografting 2016

www.critical-issues-congress.com

TIPS AND TRICKS: Percutaneous access

G Pratesi, MD

Vascular Surgery Policlinico Tor Vergata University of Rome "Tor Vergata"



Disclosure

Giovanni Pratesi, M.D.

I have the following potential conflicts of interest to report:

- ✓ Consulting: Abbott, Cook, Cordis, Medtronic, WL Gore & Associates
- □ Employment in industry
- ☐ Stockholder of a healthcare company
- ☐ Owner of a healthcare company
- \square Other(s)
- ☐ I do not have any potential conflict of interest




EVAR and percutaneous access: an ideal combination

- Rapid, safe and effective
- Local anesthesia
- Lower risk of wound-related complications (eg, seroma, infection, nerve injury)
- Reduced discomfort for the patient
- Early ambulation, shorter hospitalization
- Totally endovascular, minimally invasive procedure




Suture mediated closure devices: Prostar XL & Proglide







Learning curve in percutaneous access: a multifactorial strategy



1. Preoperative evaluation






2. Ultrasound guided puncture





3. Double Proglide technique



Approved for large bore sheath up to 21 Fr

4. Progressive closure



5. Post-closure duplex and CT follow-up access sites examination





A Systematic Literature Review of the Efficacy and Safety of the Prostar XL Device for the Closure of Large Femoral Arterial Access Sites in Patients Undergoing Percutaneous Endovascular Aortic Procedures

| Outcome | Effect measure | Absolute rate, n/N OR total patient number | Pooled result, effect size (95% CI) — random- effects model | Pooled result, effect size (95% CI) — fixed-effects model |
|--|---|---|--|--|
| Absolute rate of procedural success (access sites) | Average success rate with Prostar XL | 624/692 | 91% (87%—95%) | 92% (91–94%) |
| Absolute rate of procedural success (patients) | Average success rate with Prostar XL | 426/481 | 89% (84%—94%) | 92% (90–95%) |
| Total procedural time | Difference in procedural time between Prostar XL and surgical cut-down (weighted mean) | N = 193 | 62.4 (27.8–97.1) min | 66.1 (57.7–74.4) |
| Complication rate | Risk ratio for complications (risk with Prostar XL 10 vs. Risk with surgical cut-down) | N = 189 | 0.87 (0.41-1.88) | 0.94 (0.51–1.72) |

The Prostar XL is an effective and safe device for use in percutaneous closure of large femoral artery sites, comparable to open surgical femoral artery cut-down

Haulon S et al., Eur J Vasc Endovasc Surg 2011



Outcomes of total percutaneous endovascular aortic repair for thoracic, fenestrated, and branched endografts

2009-2014: 102 pts; total percutaneous closure was performed using two Perclose devices in 170 femoral arteries with ≥20F-diameter sheaths in 163 (96%)

- Techincal success: 95%
- 3 thrombosis, 1 retrop hematoma, 1 pseudoaneurysm
- No access-related complications
 >30 days

Table II. Aneurysm extent and sheath size in 102 patients treated by thoracic, fenestrated, and branched stent grafts using percutaneous closure

| Variable | No. (%) | | |
|-------------------------|----------|--|--|
| Type of repair | | | |
| Pararenal | 48 (47) | | |
| Thoracoabdominal | 27 (26) | | |
| Thoracic | 19 (19) | | |
| Aortoiliac | 8 (8) | | |
| Sheath size (by artery) | ` ' | | |
| <20F | 7 (4) | | |
| ≥20F | 163 (96) | | |

The rate of access related complications (5%) is similar to that reported for PEVAR of infrarenal AAAs using smaller-profile devices.

De Souza LR et al., J Vasc Surg 2015



Italian Percutaneous EVAR (IPER) Registry: outcomes of 2381 percutaneous femoral access sites' closure for aortic stent-graft

G. PRATESI 1, M. BARBANTE 1, R. PULLI 2, A. FARGION 2, W. DORIGO 2 R. BISCEGLIE 1, A. IPPOLITI 1, C. PRATESI 2 on behalf of IPER Registry Collaborators

192 TEVAR/f-bEVAR
Technical success: 96.9%


2189 EVAR
Technical success: 96.3%

| | TEVAR/f-bEVAR (192/2381) | EVAR (2189/2381) | p |
|------------------------------|-----------------------------|---------------------|------|
| Fr device (mean ± SD) | 21.3 ± 2.1 | 16.7 ± 3.4 | .03 |
| Profile > 20 Fr | 54 (43.5%) | 482 (21.3%) | .001 |
| CFA diameter, mm (mean ± SD) | 8.4 ± 1.7 | 8.2 ± 1.4 | .15 |
| CFA < 7 mm | 9 (7.2%) | 163 (7.2%) | .54 |
| High CFA bifurcation | 2 (1.6%) | 64 (2.8%) | .32 |
| CFA stenosis >50% | 6 (4.8%) | 66 (2.9%) | .16 |


J Cardiovasc Surg 2015




How to improve outcomes in pEVAR: tips & tricks



pEVAR tips & tricks: one Proglide up to 14F femoral access




pEVAR tips & tricks: sheath downsizing during complex f/bEVAR






pEVAR: tips & tricks pledgets with minor bleeding






pEVAR: tips & tricks third Proglide if you are not satisfied







pEVAR: tips & tricks endoclamping in case of failure



Expanding pEVAR applicability: toward a 100% percutaneous closure





Expanding pEVAR applicability: obese patient






Expanding pEVAR applicability: calcified common femoral arteries





Expanding pEVAR applicability: calcified common femoral arteries





Expanding pEVAR applicability: calcified common femoral arteries

